Duocarmycin DM

Duocarmycin DM

• UNSPSC Description: Duocarmycin DM, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity[1][2].
• Target Antigen: ADC Cytotoxin; DNA Alkylator/Crosslinker
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/duocarmycin-dm.html
• Solubility: 10 mM in DMSO
• Smiles: OC1=C2C(C=CC=C2)=C3C(N(C[C@H]3CCl)C(C4=CC5=C(N4)C=CC(OCCN(C)C)=C5)=O)=C1.OC(C(F)(F)F)=O
• Molecular Weight: 577.98
• References & Citations: [1]Patil PC, et al. A Short Review on the Synthetic Strategies of Duocarmycin Analogs that are Powerful DNA Alkylating Agents. Anticancer Agents Med Chem. 2015;15(5):616-630.|[2]Koch MF, et al. Structural, Biochemical, and Computational Studies Reveal the Mechanism of Selective Aldehyde Dehydrogenase 1A1 Inhibition by Cytotoxic Duocarmycin Analogues. Angew Chem Int Ed Engl. 2015 Nov 9;54(46):13550-4.|[3]Chen KC, et al. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Mol Pharm. 2013;10(5):1773-1782.|[4]Tietze LF, Krewer B, von Hof JM, Frauendorf H, Schuberth I. Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065. Toxins (Basel). 2009;1(2):134-150. |[5]Tietze LF, Schuster HJ, Schmuck K, Schuberth I, Alves F. Duocarmycin-based prodrugs for cancer prodrug monotherapy. Bioorg Med Chem. 2008;16(12):6312-6318.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported